Nomura Securities Upgrades Novo Nordisk (NVO) to Buy Post CRL Sell-Off

February 12, 2013 8:04 AM EST
Get Alerts NVO Hot Sheet
Price: $35.53 -0.28%

Rating Summary:
    8 Buy, 9 Hold, 2 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade NVO Now!
Join SI Premium – FREE
Nomura Securities upgraded Novo Nordisk (NYSE: NVO) from Neutral to Buy, which follows Monday's 14 percent sell-off after the company received a CRL from the FDA regarding the NDA for Tresiba and Ryzodeg.

For an analyst ratings summary and ratings history on Novo Nordisk click here. For more ratings news on Novo Nordisk click here.

Shares of Novo Nordisk closed at $165.40 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Hot Upgrades, Upgrades

Related Entities


Add Your Comment